Iron and steatohepatitis. by Corradini, Elena & Pietrangelo, Antonello
CELL DEATH REGULATION IN ASH AND ALCOHOLIC PANCREATITIS
Iron and steatohepatitis
Elena Corradini and Antonello Pietrangelo
Division of Internal Medicine 2 and Center for Hemochromatosis, “Mario Coppo” Liver Research Center, University Hospital of Modena,
Modena, Italy
Abstract
As the main iron storage site in the body and the main source of the iron-regulatory
hormone, hepcidin, the liver plays a pivotal role in iron homeostasis. A variable degree of
hepatic iron accumulation has long been recognized in a number of chronic liver diseases.
Both alcoholic and non-alcoholic steatohepatitis display increased iron deposits in the liver,
with an hepatocellular, mesenchymal, or mixed pattern, and recent reports have docu-
mented a concomitant aberrant hepcidin expression that could be linked to different
coincidental pathogenic events (e.g. the etiological agent itself, necroinflammation, meta-
bolic derangements, genetic predisposition). The present study reviews the pathogenic
mechanisms of iron accumulation in steatohepatitis during alcoholic and non-alcoholic
liver disease and the role of excess iron in chronic disease progression.
Correspondence
Professor Antonello Pietrangelo, Division of Internal Medicine 2 and Center for Hemochromato-
sis, “Mario Coppo” Liver Research Center, University Hospital of Modena, Via del Pozzo 71,
Modena 41100, Italy. Email: antonello.pietrangelo@unimore.it
Key words
alcoholic liver disease, fatty liver disease,
hepcidin, iron, steatohepatitis.
Accepted for publication 15 November 2011.
Introduction
In spite of the diverse etiology, alcoholic liver disease (ALD) and
non-alcoholic fatty liver disease (NAFLD) share many epidemio-
logical, clinical, and pathogenetic features. They both represent
major causes of chronic liver disease worldwide,1,2 and both
encompass a spectrum of disorders ranging from simple fatty liver
(steatosis) to hepatocyte injury and inflammation (alcoholic ste-
atohepatitis [ASH] and non-alcoholic steatohepatitis [NASH]),
cirrhosis, and superimposed hepatocellular carcinoma (HCC).
However, only a minority of individuals with steatosis of alcoholic
or non-alcoholic origin progress to more severe forms of liver
disease, indicating that factors other than the primary noxae
(alcohol in ALD and aberrant hepatic free fatty acid [FA] flux in
NAFLD) are involved in this transition.
Hepatocellular and/or mesenchymal iron deposition, usually
slight or mild, might be found in chronic non-cirrhotic liver
disease, regardless of its cause.3 Various non-specific factors
(mainly inflammation and cell necrosis), together with poly-
morphisms in iron-related genes or pathogenic interactions
between iron itself and the etiological agent (hepatotropic virus,
alcohol, increased supply of free FA to the liver or insulin resis-
tance), might be responsible. The clinical relevance of iron
excess, in terms of fibrosis development and cancer risk, is still
debated.
Regarding ALD and NAFLD, increasing data from experimen-
tal and clinical studies indicate that iron might sustain disease
activity and/or contribute to its progression. Furthermore, the
coexistence of both ALD and NAFLD risk factors, and/or the
presence of comorbidities (e.g. hepatitis C virus [HCV] and hepa-
titis B virus chronic viral hepatitis, variants of genes encoding
proteins involved in iron homeostasis) might have additive or
synergistic effects on both tissue injury and iron loading.4
Although the pathogenic mechanisms underlying ALD and
NAFLD are increasingly elucidated, therapeutic strategies are
limited. Therefore, a further dissection of the role of iron in the
pathogenesis of ALD and NAFLD could generate alternative
and/or complementary therapeutic approaches for these common
liver diseases.5
Iron homeostasis
Iron is a double-edged element. It is essential for growth and
survival, due to its crucial role in many cellular functions, such as
hemoglobin and DNA synthesis, mitochondrial respiration, oxida-
tive phosphorylation, and other enzymatic functions. However,
because of its ability to participate in the Fenton and Haber–Weiss
chemistry, excess redox-active iron might lead to reactive oxygen
species production, with consequent damage to membranes, pro-
teins, and DNA.6
Given the essential need for iron, and the fact that in mamma-
lians there is no active mechanism for iron excretion, a tight
regulation of iron absorption and recycling is required. The central
regulator of iron homeostasis is hepcidin, a small peptide hormone
Antonello
Pietrangelo
doi:10.1111/j.1440-1746.2011.07014.x
42 Journal of Gastroenterology and Hepatology 27 (2012) Suppl. 2; 42–46
© 2012 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd
synthesized mainly by the liver and secreted in the bloodstream.7 It
acts by binding ferroportin, the sole iron exporter present at
the surface of duodenal enterocytes, macrophages, placental cells,
and hepatocytes, leading to its degradation, with consequent
reduced iron absorption from the gut, and increased iron retention
in macrophages. Several stimuli have been shown to influence
hepcidin expression. Both circulatory and tissue iron upregulate
hepcidin transcription,8 via the Bone Morphogenetic Protein-
Small Mothers Against Decapentaplegic (BMP-SMAD) signaling
cascade, as a negative feedback mechanism that protects the body
from excessive iron accumulation. Inflammation also stimulates
hepcidin transcription, mainly via the Signal Transducer and
Activator of Transcription 3 (STAT3) signaling pathway, as a pro-
tective innate immune defense to limit iron availability for invad-
ing pathogens or tumoral cells. However, if upregulation of
hepcidin persists, iron-restricted erythropoiesis and anemia of
chronic disease will follow. Recently, endoplasmic reticulum (ER)
stress due to a variety of pathological signals has been shown to
trigger hepcidin expression,9 indicating that not only extracellular,
but also intracellular signals, might influence hepcidin levels
and systemic iron homeostasis. Inhibitory stimuli for hepcidin
also exist, such as iron depletion, hypoxia, and erythropoietic
activity.10
In addition, it must be considered that in end-stage liver disease,
regardless of its cause, a decreased hepcidin synthesis due to the
reduced hepatocytic mass might also lead to excess iron
deposition.
Iron in ALD and NAFLD
Alcoholic liver disease
Varying degrees of hepatic iron burden have been reported in
patients with ALD. In alcohol users, serum iron markers have been
shown to be raised even at early age.11 With increasing and per-
sistent alcohol abuse, iron accumulates in the liver, first in peri-
portal hepatocytes, and later in Kupffer cells (KC).12 Whole-body
retention studies have demonstrated that alcoholics have a twofold
increase in intestinal iron absorption.13 The degree of iron overload
in ALD is usually relatively mild, but sometimes, particularly in
the presence of cirrhosis, it is sufficiently severe to be mistakenly
attributed to hereditary hemochromatosis (HH). There might be
different reasons for iron accumulation in ALD and ASH. Both
alcohol-induced ER stress14 and inflammation might lead to hep-
cidin upregulation and iron retention in liver macrophages (Fig. 1).
However, alcohol seems also to suppress hepcidin expression in
the liver after both acute15 and chronic16,17 exposure, in vivo15,17 and
in vitro.15 In fact, ethanol downregulates the mRNA level16 and
DNA binding activity15 of CCAAT/Enhancer Binding Protein-
alpha (C/EBPa), a key transcription factor that regulates hepcidin
expression, and these effects are abolished by inhibitors of
alcohol-metabolizing enzymes and by antioxidants.15 This will
eventually lead to increased iron absorption and consequent hepa-
tocellular iron accumulation (Fig. 1). How do we reconcile these
apparently contradictory data? Most likely, both mechanisms are
operative in ALD, and it is the balance between these two opposed
hepcidin-regulating stimuli and the modifying activity of cofactors
(e.g. comorbidities, genetics, liver disease stage, and necroinflam-
matory activity) that will eventually determine the extent and
distribution of hepatic iron deposits during the course of chronic
ALD. Yet alcohol-induced hepcidin downregulation seems to play
a dominant role in iron loading, particularly in hepatocytes, where
iron can exacerbate cellular injury in a noxious vicious circle. In
fact, patients with both acute and chronic ALD show decreased
serum hepcidin levels, which progresses along with the progres-
sion of the underlying liver disease.18 When inflammatory and/or
ER stress responses predominate, the superimposed upregulation
of hepcidin might contribute to iron retention in KC, which will
then result in perturbation of their function and release of pro-
inflammatory cytokines19,20 (Fig. 1) (see also below). Yet the
inhibitory effect of alcohol on hepcidin expression seems to be
hierarchically dominant. In fact, experimental ethanol administra-
Figure 1 Molecular pathways leading to
hepatic iron overload through hepcidin modu-
lation in alcoholic steatohepatitis (ASH) and
non-alcoholic steatohepatitis (NASH). Putative
pathways that lead to hepcidin stimulation or
inhibition in ASH and NASH are shown, and
the opposite effect and diverse iron deposi-
tion pattern that might arise during individual
disease processes are emphasized. In addi-
tion, the role of iron excess into hepatocytes
or Kupffer cells and relevant molecular path-
ways leading to disease progression and
hepatocellular carcinoma are shown. ER,
endoplasmic reticulum; HCC, hepatocellular
carcinoma; HFE, human hemochromatosis
gene HFE; LPS, lipopolysaccharide.
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tion in vitro16 and in vivo17 blunts interleukin-6- 16 or iron-
mediated17 hepcidin upregulation in the liver.
As to the effect of excess iron on ALD progression, the presence
of iron has been reported to be predictive of death21 and HCC22
development in alcoholic cirrhosis. Interestingly, in patients with
HH, alcohol intake is a major determinant for phenotype severity
and liver damage.23,24 Other sets of data show a correlation
between body iron burden and the extent of fibrosis in ALD
patients, as reviewed by Tavill and Qadri.25 Therefore, clinical
evidence exists that iron and alcohol synergistically contribute to
exacerbate both hepatic iron burden and liver injury.
What about the underlying pathogenic mechanisms? Alcohol
promotes the main pathological features of ASH (i.e. hepatocyte
injury and death, inflammation, and fibrosis) by different mecha-
nisms, including alcohol/driven oxidative stress, lipopolysaccha-
ride toxicity, due the increased gut permeability,1 and ER stress.14
However, iron itself generates reactive oxygen species, inducing
lipid peroxidation and oxidation of proteins and nucleic acids,
leading to cell death.6 On the basis of the ability of both alcohol
and iron to cause oxidative stress, stellate cell activation, and
hepatic fibrogenesis, a synergistic effect on liver disease progres-
sion can be postulated (Fig. 1).26 Another pathogenically relevant
factor is in which hepatic cell type iron accumulates. While the
pathogenic role of iron inside the hepatocytes on favoring cell
damage and necrosis is obvious, excess iron accumulation in KC
has recently emerged as a central event in hepatic toxicity in ALD
(Fig. 1). In fact, the increased iron content of KC has been shown
to induce the expression and release of the pro-inflammatory
cytokine tumor necrosis factor-a and to activate the transcription
factor nuclear factor-kb in experimental animal models of
ALD.19,20 These effects are abolished by treatment of KC in vitro
and ex vivo with iron chelators.19,27
NAFLD
Well-established risk factors for NAFLD are overweight and
insulin resistance, the pathogenic cornerstones of the metabolic
syndrome (MS).2 The prevalence of NAFLD increases with the
degree of obesity,28 and is very high in type 2 diabetics.29 In fact,
NAFLD might be considered the hepatic manifestation of the MS.2
Obesity plays a crucial role in the pathogenesis of NAFLD through
the increased flux of free FA in the liver (from diet, adipose tissue,
and de novo lipogenesis), which promotes hepatic steatosis.30 The
latter results from an imbalance between free FA acquisition and
removal by oxidation or export as triglyceride into very low-
density lipoproteins.28,30 However, while approximately 80% of
obese individuals and 70% of those with type 2 diabetes present
with hepatic steatosis, only a minority of them progress to
NASH.31 Most likely, environmental and genetic factors influence
the development and progression of NAFLD.2,32 Direct hepatocyte
lipotoxicity, oxidative injury due to free radicals produced during
free FA oxidation, cytokine-mediated cellular stress, and ER stress
are the main mechanism leading to cell damage, stellate cells
activation, collagen deposition, and progression to fibrosis in
NAFLD.2,28
The presence of iron further complicates the complex pathoge-
netic picture of NAFLD. Variable degrees of hepatic iron accumu-
lation, usually mild or moderate, are common in NAFLD.3 The
term “dysmetabolic iron overload syndrome” (DIOS),33 more
recently also referred to as “insulin resistance-associated hepatic
iron overload”,34 was first introduced to define cases of unex-
plained hepatic iron excess characterized by high serum ferritin
levels, normal serum iron, and associated metabolic abnormalities.
The histological pattern of DIOS was described as mixed paren-
chymal and mesenchymal in 85% of patients.3 In two large, recent
series of 480 Italian35 and 849 American36 NAFLD patients,
hepatic iron deposition was found in approximately 50% and 35%
of cases, respectively, with an hepatocytic, mesenchymal, or
mixed pattern. Serum ferritin levels are commonly raised in
NAFLD, due to hepatic iron overload, hepatic or systemic inflam-
mation, oxidative stress, and likely insulin resistance.37 As DIOS
and hyperferritinemia associated with the MS or NAFLD share
many clinical and epidemiological features, they could be consid-
ered two different faces of the same health problem.38
Although hepatic iron excess is common in NAFLD patients,
its cause and clinical significance are still being debated. Early
in vitro studies have suggested that insulin, due to its ability to
stimulate cellular uptake of nutrients, might also cause increased
iron uptake.37 However, more recent reports have suggested that
hepcidin might be directly responsible for iron disturbances
during NAFLD. Bekry et al.39 have shown the ectopic expression
of hepcidin in white adipose tissue in obese individuals; hepcidin
mRNA levels were increased and correlated with the inflamma-
tory state, independently of steatosis and NASH. Moreover,
leptin, which is commonly increased in obesity, was demonstrated
to enhance hepcidin mRNA expression in vitro through the Janus
Kinase 2 (JAK2)/STAT3 signaling pathway,40 and a significant
positive correlation between serum leptin and hepcidin has been
reported in obese children.41 Additional factors that might contrib-
ute to hepatic iron excess in NAFLD are necrosis,42 which might
lead to iron leaking from dying hepatocytes and subsequent
phagocytosis by liver macrophages, or the induction of hepcidin
by inflammatory cytokines,7 causing iron accumulation in KC
(Fig. 1). In agreement with this hypothesis, a recent study on MS
patients, with and without NASH, reported increased hepcidin
levels compared to matched controls.43 Interestingly, hepcidin was
positively correlated with hepatic lobular inflammation in NASH,
non-NASH patients, and in the whole MS group, while in the
NASH group, it was also positively correlated with the NAFLD
Activity Score (NAS) score (which accounts for steatosis, inflam-
mation, and hepatocyte ballooning). Interestingly, none of the MS
patients had increased iron load at the liver biopsy, indicating that
high hepcidin was not due to tissue iron excess, but most likely to
necroinflammation per se. An additional trigger for hepcidin acti-
vation in these patients is likely ER stress (a known activator of
hepcidin expression), which has been associated with NAFLD
and its main risk factors, namely obesity and type 2 diabetes28
(Fig. 1). Conversely, as oxidative stress has been shown to down-
regulate hepcidin expression in ALD15 or HCV-related44 liver
disease, the same phenomenon might well occur in NASH, where
oxidative stress is well documented. Controversy surrounds the
relationship between the human hemochromatosis gene HFE
polymorphisms with both liver iron accumulation and the risk of
fibrosis in NAFLD.38 The discrepancy among different studies
might be due to different ethnicities, patient inclusion criteria, and
referral bias.
In summary, in analogy with ALD, during the dynamic evolu-
tion of NAFLD, diverse signals might arise that modulate hepcidin
Iron and steatohepatitis E Corradini and A Pietrangelo
44 Journal of Gastroenterology and Hepatology 27 (2012) Suppl. 2; 42–46
© 2012 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd
expression in the opposite direction, depending on patient genetic
determinants, comorbidities, timing and entity of the primary liver
injury, and liver disease stage or inflammatory activity. So far,
available data seem to indicate that in NAFLD hepcidin induction
by systemic inflammation (related to obesity), intrahepatic inflam-
mation, and/or intrahepatic cytokine-related stress and ER stress
(secondary to excessive free FA influx) has a central role in iron
retention in the liver, and likely in white adipose tissue (Fig. 1).
As to the effect of hepatic iron accumulation on disease pro-
gression, a recent study, while failing to detect a correlation
between the presence of HFE mutations and the severity of hepatic
fibrosis, showed that hepatocellular iron accumulation was asso-
ciated with more severe liver fibrosis.35 In contrast, another study
reported that reticuloendotelial iron accumulation is correlated
with the histological features of NASH (inflammation, hepatocyte
ballooning, and fibrosis) and with advanced fibrosis.36 As it is
known that iron load in KC could impair their function19,20,27
(Fig. 1), this event might also contribute to disease progression.4
Interestingly, heterozygosity for the C282Y mutation of HFE gene
has been associated with lower insulin release and the develop-
ment of NAFLD,45 suggesting that HFE mutations and/or the
consequent, even mild, iron overload might act as facilitator of the
disease. Finally, a significant relationship between hepatic iron
content and HCC progression has been reported, suggesting a
carcinogenic or cocarcinogenic role for iron in NASH.42
What about the pathogenic mechanisms underlying the effect of
iron load on the progression of NAFLD? Both free FA2,28 and iron6
excess in the liver have been demonstrated to induce oxidative
injury, indicating that when hitting the liver together, they might
exert a synergistic hepatotoxic effect. In the same vein, accumulat-
ing evidence suggests that hepatic mitochondrial dysfunction might
contribute to NAFLD development and severity,46 as occurs in
experimental iron overload.6 A number of studies suggest that
hyperglycemia, hyperinsulinemia, and adipokines secreted by the
adipose tissue might have a direct fibrogenic role, independently of
hepatocyte injury and stellate cell activation.32 Hepatic iron excess
might contribute to the impairment of glucose homeostasis by
influencing insulin signaling. In fact, iron removal by phlebotomy
or iron chelators has been shown to improve insulin sensitivity
and/or metabolic control in healthy individuals, type 2 diabetics,
and NAFLD patients,37,47,48 reinforcing the idea of a possible role of
iron in favoring insulin resistance, which is a main factor involved
in NAFLD progression and severity.
Ferritin levels also have been shown to correlate with the sever-
ity of NAFLD, both in the absence49 or presence50 of hepatic iron
load, and independently of type 2 diabetes, body mass index, age,
sex, and hepatic iron deposition.50 This suggests that ferritin per se
might exert a role on disease progression in NASH through still
undefined mechanisms.
Conclusions and perspectives
Both ALD and NAFLD are commonly associated with varying
degrees and diverse patterns of hepatic iron deposition, whose
cause and significance are being progressively elucidated.
In both conditions, a direct modulation of hepcidin expression
by the causative agent (alcohol or fat) might play a role in the
modification of systemic and/or intrahepatic iron traffic, leading to
tissue iron load. While during the long -lasting course of ALD and
NAFLD opposite regulatory forces on hepcidin expression might
cause diverse patterns of hepatic iron accumulation, alcohol-
induced hepcidin downregulation seems to play a dominant role in
hepatocytic iron loading in ALD, while necroinflammation favors
preferential iron deposits in KC in NAFLD. Once liver iron burden
is established, it might act at both the hepatocellular and mesen-
chymal levels to maintain and enhance liver injury and disease
progression, regardless of its cause (Fig. 1).
Further studies are needed to elucidate the molecular events that
link iron excess and the clinical features of ALD and NAFLD, or
the consequence of different patterns of tissue iron accumulation
on disease severity. Nevertheless, in view of the available experi-
mental and clinical data, it is time to consider the use of iron-
removal strategies as adjuvant therapy in patients with ASH and
NASH. Ideally, iron removal should be achieved by using perme-
able, hepatotropic “weak” iron chelators able to target the redox-
active intracellular iron pool in hepatocytes and KC without
affecting the circulatory iron pool or systemic iron stores (the
drawback of phlebotomy).
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